BRPI0715712A2 - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BRPI0715712A2
BRPI0715712A2 BRPI0715712-6A2A BRPI0715712A BRPI0715712A2 BR PI0715712 A2 BRPI0715712 A2 BR PI0715712A2 BR PI0715712 A BRPI0715712 A BR PI0715712A BR PI0715712 A2 BRPI0715712 A2 BR PI0715712A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0715712-6A2A
Other languages
English (en)
Inventor
Simon Banks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0715712(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0715712A2 publication Critical patent/BRPI0715712A2/pt
Publication of BRPI0715712B1 publication Critical patent/BRPI0715712B1/pt
Publication of BRPI0715712B8 publication Critical patent/BRPI0715712B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0715712A 2006-08-21 2007-08-20 composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina BRPI0715712B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21
US60/823083 2006-08-21
PCT/SE2007/000736 WO2008024045A1 (en) 2006-08-21 2007-08-20 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate

Publications (3)

Publication Number Publication Date
BRPI0715712A2 true BRPI0715712A2 (pt) 2014-06-24
BRPI0715712B1 BRPI0715712B1 (pt) 2021-03-23
BRPI0715712B8 BRPI0715712B8 (pt) 2021-05-25

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715712A BRPI0715712B8 (pt) 2006-08-21 2007-08-20 composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina

Country Status (35)

Country Link
US (2) US8425934B2 (pt)
EP (1) EP2056832B1 (pt)
JP (2) JP5385139B2 (pt)
KR (1) KR101539467B1 (pt)
CN (1) CN101505754A (pt)
AR (1) AR062451A1 (pt)
AU (2) AU2007288541B9 (pt)
BR (1) BRPI0715712B8 (pt)
CA (1) CA2659328C (pt)
CL (1) CL2007002421A1 (pt)
CO (1) CO6150163A2 (pt)
CY (1) CY1119380T1 (pt)
DK (1) DK2056832T3 (pt)
ES (1) ES2625930T3 (pt)
HR (1) HRP20170694T1 (pt)
HU (1) HUE031939T2 (pt)
IL (2) IL196700A (pt)
LT (1) LT2056832T (pt)
MX (1) MX340403B (pt)
MY (2) MY147966A (pt)
NO (1) NO341787B1 (pt)
NZ (2) NZ596700A (pt)
PH (1) PH12013501627A1 (pt)
PL (1) PL2056832T3 (pt)
PT (1) PT2056832T (pt)
RS (1) RS55884B1 (pt)
RU (2) RU2476223C2 (pt)
SA (1) SA07280442B1 (pt)
SG (1) SG177162A1 (pt)
SI (1) SI2056832T1 (pt)
TW (1) TWI482772B (pt)
UA (1) UA99105C2 (pt)
UY (1) UY30551A1 (pt)
WO (1) WO2008024045A1 (pt)
ZA (1) ZA200900991B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
EA026094B1 (ru) * 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EA201501164A1 (ru) 2013-05-29 2016-08-31 Рациофарм Гмбх Твердая фармацевтическая лекарственная форма
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
RU2707959C2 (ru) * 2015-01-27 2019-12-03 Астразенека Аб Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
ES2907489T3 (es) * 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh) 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
EP3761965A1 (en) 2018-03-08 2021-01-13 Pharmaceutical Oriented Services Ltd Ticagrelor-containing tablet formulation
SI3829547T1 (sl) 2018-07-27 2025-10-30 Krka, D.D., Novo Mesto Farmacevtska sestava tikagrelorja
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
US20240285636A1 (en) * 2021-06-14 2024-08-29 Libbs Farmacêutica Ltda Pharmaceutical composition and use of the pharmaceutical composition
EP4608433A1 (en) 2022-10-28 2025-09-03 Astrazeneca AB Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
US20050119281A1 (en) 2002-02-15 2005-06-02 Biogal Gyogyszergyar Rt Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
US20060039968A1 (en) 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
AU2003274410A1 (en) 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
CN101068570A (zh) 2004-05-13 2007-11-07 贝林格尔·英格海姆国际有限公司 双嘧达莫治疗血小板抑制剂的抗药性的用途
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
KR101203118B1 (ko) * 2005-01-31 2012-11-20 옵티머 파마슈티칼즈, 인코포레이티드 18-원자 거대고리들 및 그 유사체들
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
AU2011205164A1 (en) 2011-08-25
HRP20170694T1 (hr) 2017-07-28
KR20090055561A (ko) 2009-06-02
NO20090425L (no) 2009-03-05
SI2056832T1 (sl) 2017-07-31
KR101539467B1 (ko) 2015-07-24
UA99105C2 (ru) 2012-07-25
AR062451A1 (es) 2008-11-12
SA07280442B1 (ar) 2012-04-07
NZ596700A (en) 2013-05-31
AU2007288541B9 (en) 2011-10-06
JP2014040448A (ja) 2014-03-06
SG177162A1 (en) 2012-01-30
JP2010501554A (ja) 2010-01-21
RU2012153069A (ru) 2014-06-10
NZ574514A (en) 2012-01-12
UY30551A1 (es) 2008-03-31
US20130131087A1 (en) 2013-05-23
BRPI0715712B1 (pt) 2021-03-23
CO6150163A2 (es) 2010-04-20
CA2659328C (en) 2015-08-11
ZA200900991B (en) 2010-02-24
DK2056832T3 (en) 2017-05-22
AU2007288541A1 (en) 2008-02-28
MY175009A (en) 2020-06-02
AU2007288541B2 (en) 2011-08-25
CY1119380T1 (el) 2018-02-14
CN101505754A (zh) 2009-08-12
CL2007002421A1 (es) 2008-04-04
TWI482772B (zh) 2015-05-01
TW200817412A (en) 2008-04-16
EP2056832B1 (en) 2017-03-22
CA2659328A1 (en) 2008-02-28
EP2056832A1 (en) 2009-05-13
WO2008024045A1 (en) 2008-02-28
ES2625930T3 (es) 2017-07-21
MX2009001853A (es) 2009-03-02
JP5385139B2 (ja) 2014-01-08
HUE031939T2 (en) 2017-08-28
RS55884B1 (sr) 2017-08-31
EP2056832A4 (en) 2012-12-26
RU2009104330A (ru) 2010-09-27
US8425934B2 (en) 2013-04-23
LT2056832T (lt) 2017-05-25
RU2476223C2 (ru) 2013-02-27
PT2056832T (pt) 2017-05-22
IL229130A0 (en) 2013-12-31
MY147966A (en) 2013-02-28
NO341787B1 (no) 2018-01-22
US20080058353A1 (en) 2008-03-06
IL196700A0 (en) 2009-11-18
PL2056832T3 (pl) 2017-09-29
AU2011205164B2 (en) 2014-02-06
MX340403B (es) 2016-07-07
BRPI0715712B8 (pt) 2021-05-25
PH12013501627A1 (en) 2014-11-10
IL196700A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0716325A2 (pt) Composição antimicrobianas
RU2493831C3 (ru) Фармацевтические композиции
RU2398586C3 (ru) Фармацевтическая композиция
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0810928A2 (pt) "composição farmacêutica"
DK2120884T3 (da) Farmaceutisk sammensætning
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2043136A4 (en) FILMING COMPOSITION
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
FR2899479B1 (fr) Composition cicatrisante
BRPI0716458A2 (pt) Composição de vulcanizado
DK2285413T3 (da) Farmaceutisk sammensætning
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: EMS.S.A - 870210086832 - 21/09/2021